Osteopontin (OPN), bone sialoprotein (BSPII), and osteonectin (ON) belong to a family of glycoproteins, which have been linked to cancer metastasis and progression. Here, we report on the selection of antisense oligonucleotides (ASOs), which are effective in reducing their protein levels. In human MDA-MB-231 breast cancer cells, the maximum inhibition of protein expression ranged from 84% (OPN) to 75% (BSPII) and 70% (ON). Erucylphospho-NNN-trimethylpropanolamine (ErPC 3 ) was used as positive control and combination partner. Exposure to ErPC 3 inhibited colony formation of MDA-MB-231 cells by 11% (10 mM), 45% (14 mM) and 78% (20 mM). The clonogenicity of breast cancer cells was reduced by 15%, 11%, 8% (5 mM), 39%, 19%, 14% (10 mM) and 46%, 39%, 21% (20 mM) in response to ASO-OPN-04, ASO-BSPII-06 and ASO-ON-03, respectively. Combination of ErPC 3 with the ASOs caused additive combination effects. Pre-exposure to the ASOs, but not to the NSO, inhibited formation of osteolytic metastasis in three of four (ASO-OPN-04, Po0.03) and two of four (ASO-BSPII-06) nude rats, and reduced metastasis lesions significantly (T/C% ¼ 4.3 and 9.1, P ¼ 0.05, respectively). We conclude that downregulation of OPN and BSPII reduces colony formation of MDA-MB-231 cells and formation of osteolytic metastasis in nude rats.
C
ancer is a life-threatening disease, not as a result of the primary tumor that can be removed surgically in the vast majority of cases but from its metastatic spread to adjacent and distal sites in the body. Currently used diagnostic techniques do not accurately reflect progression or metastatic spread of a cancer, but recently some evidence has accumulated with respect to markers that are related to the development of progression and metastasis. One molecule of this promising group of markers is the secreted adhesive glycophosphoprotein osteopontin (OPN). This molecule has recently been recognized as a lead marker of human colon cancer progression as shown by a significant correlation between OPN protein expression and advanced tumor stage. 1 Similarly, OPN was found to be a metastasis-associated protein in human breast cancer in that overexpression of OPN in breast tumors as well as in blood of patients was highly correlated with tumor progression.
2,3 OPN was initially described as a protein, the secretion of which was elevated in many transformed cells in culture. 4 Besides this fact, it was also identified as a major noncollagenous protein in bone. 5 Moreover, it is a calcium-binding protein that is important in bacterial resistance and immune activity 6 as well as in cell adhesion, signaling, migration and survival of various cells, in addition to being a potent regulator of osseous and ectopic calcification. 7, 8 OPN and bone sialoprotein (BSPII) are members of the small integrinbinding ligand, N-linked glycoprotein (SIBLING) family of genetically related proteins that are clustered on the long arm of human chromosome 4. 9 These proteins often function by bridging two proteins of fixed structures into a biologically active complex. The structural similarity of BSPII with OPN is paralleled by the observation that both proteins are expressed by certain tumor cells such as breast cancer, 10, 11 as well as colon, prostate 12 and lung cancer, 13 and have been related to the pathogenesis of bone metastasis. 8 The calcium binding properties of BSPII 14 and its role in initiating and controlling hydroxylapatite crystallization 15 have been related to the formation of microcalcification in breast cancer. Osteonectin (ON) is a third molecule that has been related to progression of human colorectal 16 and urinary bladder cancer 17 as well as to bone metastasis. 18 It is a noncollagenous, calcium-binding glycoprotein that has been mapped to the long arm of chromosome 5 19 and is related to wound healing 20 and angiogenesis. 21 We considered the three proteins to be potential targets for treatment in order to slow down or suppress the formation of bone metastasis. For a specific treatment, we identified antisense oligonucleotides (ASOs) that are capable of reducing the expression levels of OPN, BSPII and ON. The activity of these ASOs was determined by Western Blot and by inhibition of colony formation as well as of metastasis formation of pre-exposed MDA-MB-231 human mammary carcinoma cells. This cell line was chosen for its ability to express the three proteins, to form colonies, and to induce lytic bone metastasis in nude rats.
Materials and methods
In total, 10 cell lines were used for detecting OPN, BSP II and ON. They were selected from various organs to establish a possibly differential expression of the three proteins. Therefore, the panel consisted of cancer cells derived from the skeleton (SAOS-2), as well as of cells metastasizing into the skeleton (MDA-MB-231 and MDA-MB-435S). In addition, cells without apparent affinity to the skeleton were used for comparison (K562, HL-60, BV-173, MCF-7, T47D, HT29 and ACHN). The cell lines were obtained from the ATCC or DSZM, respectively, and were grown in media and supplements as recommended by the two organizations (fetal bovine serum (FBS), L-glutamine, insulin, NaHCO 3 , glucose, hepes and pyruvate, all from Sigma, Taufkirchen, Germany). For determining the potential secretion of OPN and bone sialoprotein, an MDA-MB-231 subline was generated, which was selected by continuously reducing the FBS content of the medium, until the cells kept growing without FBS. This cell line was denoted as MDA-MB-231
F . All cells were kept in log-phase, and passaged 1-3 times per week depending of their growth rate, and maintained under standard conditions (371C, humidified atmosphere, 5% CO 2 ).
Clonogenicity assay
For determining the response of MDA-MB-231 colony formation to exposure with ASOs and erucylphospho-NNN-trimethylpropanolamine (ErPC 3 ), the following procedure was used. MDA-MB-231 cells were treated for various periods of time (see below), harvested and counted. Cells (5000) were then transferred into semisolid medium containing 0.8% RPMI-methylcellulose and 30% FBS. Cells were plated onto 3.5 cm Petri-dishes (1 ml/dish) (NUNC, Wiesbaden, Germany) and usual cell culture conditions (371C, 5% CO 2 in humidified air) were applied. Colony formation (clusters of 30 or more cells) was visualized by staining with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium-bromide (MTT; Serva, Heidelberg, Germany) and the resulting dark blue colonies were scored by an inverted microscope after 5-7 days. At least three dishes per treatment protocol were used.
Selection of ASOs
The suitability of 10 different ASOs per gene was predicted by using the HUSAR program ''Mfold'', [22] [23] [24] which takes RNA folding into account. Application of this program onto the cDNA sequence of OPN (acc. no. gi:3360431), BSPII (acc. no. gi:11435526) and ON (acc. no. gi:14124969) resulted in the recognition of RNA stretches that probably contain bulges or loops, that is that are preferentially single stranded and thus allow access of DNA antisense structures. ASOs of 20 base pair lengths were selected against these single-stranded regions and synthesized with a phosphorothioate backbone, to increase stability against degrading enzymes (Table 1) . Controls included a nonsense oligonucleotide (NSO) derived from HBV genome that served as backbone analog to control for unspecific effects of a 20 bp long phosphorothioate oligomer. In addition, its base composition differed only slightly from the mean composition of all ASOs used (A:3 versus 4.1; C:4 versus 4.4; G:6 versus 4.8; T:7 versus 6.6). Sequence-specific effects were controlled by using ASOs differing by three base pairs with regard to the respective cDNA sequence. Finally, the use of 10 ASOs per target gene allowed to include sequences that were scrambled (identical in base composition) except for two bases that were permutated.
Exposure of cells to ASOs and ErPC 3
Stock solutions of ASOs in distilled water were diluted to appropriate concentrations with phosphate-buffered saline (PBS). For transfecting cells with ASOs, lipofectamine (Lipofectin, Invitrogen, Karlsruhe, Germany) or electroporation was used.
Electroporation
Pending on the duration of treatment, 5 Â 10 5 -3 Â 10 6 cells were suspended in 1 ml RPMI 1640 medium without phenol red containing 10 mM concentrations of the respective ASO or NSO. For transfection, the cells were pulsed two or three times for 2 ms at 450 or 350 V, respectively, in a 800 ml cuvette (Eppendorf, Hamburg, Germany) using an electroporation impulse generator (EPI2500, Dr L Fischer, Heidelberg, Germany) with the capacitance set at 1200 mF. Thereafter, the cells were plated onto six-well plates and grown for 48-72 hours.
Lipofectamine
Pending on the duration of treatment, 1 Â 10 5 -3 Â 10 5 cells were transferred onto six-well plates (Nunc, Wiesbaden, Germany) and grown for 24 hours. For transfection, ASO stock solutions were prepared in medium without FBS. According to the protocol of the manufacturer, the respective ASO stock solution was mixed with lipofectamine to allow ASO-liposome complexes to form. To 200 ml medium containing ASO quantities resulting in 10 mM (Western blot and in vivo model) and in 5, 10, or 20 mM (clonogenicity assay) final ASO concentrations, an equal volume of medium without FBS was added containing 5, 10 or 20 ml lipofectamine, respectively. In addition to the ASO treatment, an NSO control (20 mM final concentration with 20 ml lipofectamine) and a lipofectamine control (20 ml) were used. Based on the equilibrium of the ASO-liposome complex formation, the relatively low amount of lipofectamine used resulted in effective ASO concentrations that were at least by a factor of 10 lower than those in the medium used for transfection. After 12 hours the medium was changed, and cells were further grown for 48-72 hours. In the case of a sequential combination treatment this first cycle was repeated with the respective combination partner.
ErPC 3
The alkylphosphocholine ErPC 3 was synthesized and provided by Prof H Eibl (MPI of Biophysical Chemistry, Go¨ttingen, FRG). For treating MDA-MB-231 cells, ErPC 3 , which was kept as stock solution in ethanol and PBS (10 mM; ratio of diluents 1:1; V:V), was diluted in PBS resulting in final concentrations of 10, 14 and 20 mM. The medium containing ErPC 3 was changed after 24 hours in all experiments and the cells were further grown for 48-72 hours without ErPC 3 (for details of sequential exposure see below).
Combination treatment
Sequential combination treatment consisted of two or three treatment cycles. The two-cycle treatment started either with the ASO and was followed by ErPC 3 or was performed with the reverse sequence. The three-cycle treatment started either with two cycles of ASO followed by ErPC 3 or an initial exposure to ErPC 3 was followed by two cycles with an ASO.
Statistics and evaluation of combination effects
Colony counts are presented as mean with corresponding SD. For comparison of incidences between treatment groups the w 2 test was used, and for comparison of the lesion sizes the Kruskal-Wallis test was applied. 25 P-values r0.05 were considered significant. Predicted theoretical values of combinations were calculated according to the equation: C = (a Â b) /100 where a and b are colony counts in percent of untreated control obtained in response to single agents. For each concentration applied, theoretical values were calculated and compared with the real value of the combination. In addition, isobologram and multiple drug effect analysis was examined by a suitable program (CalcuSyn, Biosoft, Ferguson) to study the nature of the interaction observed. 26, 27 For this purpose, the dose-effect curve for each drug alone was determined based on the experimental observations using the median-effect principle; the combination index (CI) for each combination was then calculated according to the following equation: where (D) 1 and (D) 2 are the doses of drug 1 and drug 2 that have x effect when used in combination and (D x ) 1 and (D x ) 2 are the doses of drug 1 and drug 2 that have the same x effect when used alone. When CI ¼ 1, this equation represents the conservation isobologram and indicates additive effects. CI values less than 1.0 indicate a more than expected additive effect (synergism).
Western blotting
Transfected cells were incubated, harvested and washed in PBS. Thereafter, cells were counted (Neubauer chamber) and cell pellets (2 Â 10 6 cells) were suspended in 200 ml buffer (0.1 M NaCl, 0.01 M Tris Cl (pH 7.6), 0.001 M EDTA (pH 8.0)) containing 1 mM PMSF (Sigma), 50 mg/ ml aprotinin (Sigma), 1 mM Na 3 VO 4 , and 2 mg/ml The following sequence from HBV was used as a nonsense control: 5 0 -GCG AGG GAG TTC TTC TTC TA-3 0 . a The combination of the abbreviation of the gene and the number of a given ASO was used for its naming.
Bone sialoproteins are related to bone metastasis H Adwan et al leupeptin (Sigma). After that the cells were lysed by adding 200 ml of lysis buffer (100 mM Tris Cl (pH 6.8), 200 mM dithiothreitol (Serva, Heidelberg, Germany), 4% SDS, 0.2% bromophenol blue and 20% glycerol]. After vigorously vortexing, lysates were boiled for 10 minutes in a water bath at 1001C and centrifuged at 14,000 rpm for 10 minutes at room temperature. The protein concentration of the lysate was determined using the BCA protein assay from Pierce (Rockford, IL) according to the manufacturer's recommendation. Cell lysates corresponding to 150,000 cells were loaded onto a 6% SDS polyacrylamide gel, separated by electrophoresis and transferred to a PVDF membrane, blocked with 5% skimmed milk in PBS and incubated with the respective first antibody (OPN: rabbit-antihuman polyclonal or mouse-antihuman monoclonal antibody; ON: rabbitantihuman polyclonal; BSP II chicken-antihuman or rabbit-antihuman polyclonal (all from Immundiagnostik, Bensheim, Germany)) for 2 hours in PBS; containing 0.5% milk and 0.5% Triton X-100. After washing with PBS, containing 0.05% Tween 20, an HRP-conjugated anti-mouse, anti-rabbit or anti-chicken secondary antibody (all from Immundiagnostik, Bensheim, Germany) and ECL (Amersham Biosciences, Freiburg, Germany) were used to detect the respective proteins by exposing the membrane to an X-ray film (Kodak Biomax, Rochester, New York, NY). To control for variations in loading, the membranes were stripped for 30 minutes at 561C in stripping solution (62.5 mM Tris HCl (pH 6.8); 2% SDS; 0.007% b-mercaptoethanol). Thereafter, they were reprobed with an antibody against b-actin (mouse monoclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA), and a secondary goat anti-mouse polyclonal antibody (Santa Cruz Biotechnology).
Evaluation of band intensity for Western blot research
The X-ray films were processed by an automatic developing machine (Curix 60, Agfa, Ko¨ln, Germany) and the resulting images were scanned by using a digital imaging Program (Adobe photoshop 6.0, Adobe Systems Incorporated). Digitized bands of the respective proteins were given as percent of control and corrected for differences in loading by referring to the intensity of the b-actin band.
Animals and husbandry
Nude rats (RNU strain) were obtained from Harlan (Harlan comp, Borchen, Germany) at an age of 6-8 weeks. They were housed under specific pathogen-free conditions in a mini-barrier system of the central animal facility. Autoclaved feed and water was given ad libitum to the animals that were maintained under controlled conditions (21721C room temperature, 60% humidity, 12 hours light-dark rhythm).
In vivo model
In order to induce locoregional bone metastasis, and to investigate a preventive effect of the ASOs, 10 5 MDA-MB-231 cells (control or pre-exposed to ASOs) were injected into a secondary muscular branch of the femoral artery of a nude rat.
After an average of 28 days following the injection of control cells, lytic metastases could be detected by X-rays. The size of these lesions, which exclusively occurred in the femur, tibia and fibula of the animals, was recorded for up to 10 weeks.
Results
The expression of OPN and BSP II in a panel of 11 cell lines is shown in Figure 1 
The mouse monoclonal antibody against human OPN recognizes multiple bands with an apparent size ranging from 60 to 100 kDa.
The rabbit polyclonal antibody against human BSPII recognizes two bands with an apparent size ranging from 80 to 160 kDa. Erythrocytes served as negative control for both, the OPN and BSPII antibodies and, in addition, large bowel mucosa and white blood cells served as negative control for BSPII. Urine was taken from a normal subject and the medium was from MDA-MB-231 cells growing without FBS. Figure 2c , recognized a protein with a size of about 62 kDa. Since the expression of this protein was modulated by ASO exposure (see below), we assume that we observed a dimer.
The Western blot results of protein expression after exposing mammary carcinoma cells to ASOs directed against OPN, BSPII and ON-mRNA are shown in Table 2 and Figure 2 . Systematic comparisons showed that ASO-OPN-04, ASO-BSPII-06 and ASO-ON-03 and 05 were the most effective structures within the respective series. Single exposure of cells was enough to reduce the OPN expression by 84% in response to ASO-OPN-04. This effect was not increased by repeating the ASO exposure, but the protein concentration was kept at a comparable level (77%). A similar efficacy was obtained The inhibition of MDA-MB-231 colony formation is shown in Tables 3-6 . Single exposure to the ASOs considered optimal is shown in Table 3 . In contrast to ErPC 3 , which was used as a standard, effecting 11% (lowest concentration) to 78% (highest concentration, P ¼ 0.05, respectively) colony growth inhibition, the ASOs were less effective. Nevertheless, all ASOs reduced the colony growth concentration dependently, and this effect was significantly different from untreated control (P ¼ 0.05) except for ASO-ON-03 at 5 mM. ASO-OPN-04 caused 47% colony growth inhibition at the maximum concentration of 20 mM, ASO-BSPII-6 (39%) and ASO-ON-3 (27%) were even less effective at equimolar highest concentrations (20 mM). Serial combined exposure (Table 4) to ASO-OPN-04 (first agent) and ErPC 3 (second agent) resulted in colony growth inhibition compared to untreated control ranging from 33% (5 mM ASO OPN-4 þ 10 mM ErPC 3 ) to 93% (20 mM ASO-OPN-4 þ 20 mM ErPC 3 ). Similarly, combination of ASO-BSPII-06 with ErPC 3 caused reduction in clonogenic growth ranging from 28% (5 mM ASO-BSPII-06 þ 10 mM ErPC 3 ) to 87% (20 mM ASO-BSPII-06 þ 20 mM ErPC 3 ). Finally, combination of the ASO-ON-03 with ErPC 3 caused colony growth inhibition ranging from 14% (5 mM ASO-ON-03 þ 10 mM ErPC 3 ) to 84% (20 mM ASO-ON-03 þ 20 mM ErPC 3 ). Repeated exposure to ASO-OPN-04 (Table 5) was more effective than single exposure to this agent, as shown by colony number reduction. Two-fold exposure to ASO-OPN-04 at 5 mM reduced colony counts by 16%, and by 60% at 20 mM. Interestingly, repeated exposure to ASO-BSPII-06 caused no increased inhibition of colony formation as compared with single exposure. The combination of this treatment schedule plus a final exposure to ErPC 3 (14 mM) caused an additive effect, as shown by 76%-83% (ASO-OPN-04) and 61%-75% (ASO-BSPII-06) reduced colony numbers, respectively (Table 5 ). In a subsequent experiment, the sequence of agents was reversed (Table 6 ). Within normal experimental variation, ErPC 3 followed by two-fold exposure to ASO-OPN-04 or ASO-BSPII-06 was as effective as the reverse sequence in the preceding experiment and all The results of the bioassay are shown in Table 7 . Exposure to the ASO-OPN-04 and ASO-BSPII-06 for 3 days before implantation into nude rats caused a significantly reduced tumor take rate, as assessed by the appearance of osteolytic lesions following exposure to ASO-OPN-04, and a reduced size of osteolytic lesions in the X-ray-positive rats following both agents.
Nude rats that received 1 Â 10 5 untreated or NSOtreated MDA-MB-231 breast cancer cells developed bone metastasis in four of four cases ( Table 7) . The metastatic lesions were detectable for the first time after 4 weeks (mean size of the two control groups: 197 relative units (R.U.)) and doubled in size until week eight (mean size of the two control groups: 416 R.U.). Three of four rats that received 1 Â 10 5 MDA-MB-231 breast cancer cells pretreated with the ASO, directed against OPN, developed no discernible metastasis within the observation period (P ¼ 0.028). One of the four rats developed lytic metastasis, but this lesion was distinctly smaller in size than those in control rats (week 4: 34 R.U., 17% of control; week 8: 60 R.U., 17% of control; P ¼ 0.05). Similarly, two of four rats that received 1 Â 10 5 MDA-MB-231 breast cancer cells pretreated with the ASO directed against BSPII remained free of visible metastasis within the observation period of 8 weeks, one rat showed lytic metastasis after 4 weeks already (14 R.U., 7% of control), an other rat developed a metastasis after 8 weeks (63 R.U (mean), 15% of control; P ¼ 0.05). Thus, exposure to both, ASO-OPN-04 and ASO-BSPII-06, was associated with a significantly reduced lesion size, and the former agent caused a significantly reduced incidence of lesions, as well.
Discussion
The three noncollagenous proteins OPN, BSPII and ON are phosphorylated acidic glycoproteins, which are present in immobilized form in the extracellular matrix (ECM) of the skeleton. [28] [29] [30] They are secreted by certain tumor cells with metastatic affinity to bone tissue, as for example by breast, prostate, lung and other cancer cells. 2, 3, 12, 13, 18, [31] [32] [33] [34] In addition, they show various functions; OPN can bind to a number of receptors such as integrins as well as to certain variant forms of CD44, [35] [36] [37] it can act as a cytokine 29 and has function in the urinary tract. 31 BSPII is closely related to OPN, 38,9 but ON differs from OPN and BSPII by its chromosomal origin, its lack in an RGD binding domain, and its function that is related for example to the maintenance of lens transparency as has been described in knockout mice. 39 In addition, antisense-mediated suppression of ON has been described to inhibit motility and invasion of MCF-7 cells stably overexpressing c-jun. 40 Owing to their relationship to the progression of cancer we considered the three proteins to be potential targets of a specific, proteinrelated treatment. 37 The expression level varied between all cell lines tested, but there was no cell line without expression of OPN and BSP II. For experiments aimed at modulating their levels, we chose a cell line (MDA-MB-231) with more than average expression of OPN and BSP II, which is able to metastasize into the skeleton. 41 The metastasis model was based on using nude rats and a secondary muscular branch of the femoral artery as site of injection, thus restricting the occurrence of metastasis to one limb only (own, unpublished results).
ASOs were used to inhibit the expression of proteins. They had been chosen by the program Mfold that had been found useful in selecting antisense structures for various purposes. [42] [43] [44] These ASOs were compared by Western blot, and effective structures decreased the respective protein level by more than 70% as compared with NSO-treated cells (Table 2; Fig. 3 ). The differences in ASO efficacy are probably related to the three-dimensional accessibility of their target structure. [42] [43] [44] [45] Although all structures were selected to hybridize with preferentially single-stranded RNA stretches, the impact on protein expression varied between minimally and highly effective. For OPN, it was obvious that the ASOs directed against the start codon (ASO-OPN-01) and a loop after the stop codon (ASO-OPN-04) were most effective in downregulating the protein. The fact that an ASO directed towards a sequence after the stop codon is active in suppressing the expression of OPN hints to an activity against pre-mRNA or a triplex formation with DNA 46 and that sufficient concentrations are obtained in the nucleus. The observation is in accord with that of others, for example an ASO targeting the 3 0 -untranslated region of PKCa mRNA. 47 The comparison of two overlapping ASOs directed against four target structures, respectively, shows no significant differences between the almost identical ASOs, except for ASO-OPN-04 and ASO-OPN-05. The superiority of ASO-OPN-04 over ASO-OPN-05 might be explained by the increased accessibility of the respective target structures: whereas ASO-OPN-04 can hybridize with 17 nucleotides (85% of total ASO length) to an accessible target site, ASO-OPN-05 can do so only with 14 nucleotides (70% of total ASO length).
For BSPII, the ASO pair directed against the region of the start codon (ASO-BSPII-01 and ASO-BSPII-02) was less effective than those directed against the largest loop of the molecule (ASO-BSPII-05 and ASO-BSPII-06). From these two, ASOBSPII-06 was more effective, in line with its hybridization to a closely neighboring loop. Also, the ASO pair directed to the region of the stop codon was more effective than the average with ASO-10 being slightly superior to ASO-BSPII-09, presumably because ASO-10 can hybridize to the loop as well as a pair of unpaired nucleotides. 43 For ON, the ASO directed against the start codon (ASO-ON-1) was of average activity, as well as those directed to sites after the stop codon (ASO-ON-08 -ASO-ON-10). The highest activity was associated with two ASOs (ASO-ON-03 and ASO-ON-05) spanning over a small series of bulges. However, no ASO was really outstanding over all other structures.
With regard to the transfection method used, differences in the resulting protein level were observed in this study, for example for ASO-BSP05 and 07 when using lipofectamine and electrotransfection (Table 2 ). Such differences have been observed by others, as well. 52, 53 Overall, however, the effects were comparable, although the effective ASO concentrations were at least 10-fold lower when using lipofectamine.
When comparing the most effective ASOs, as assessed from Western blot, for their activity to reduce colony formation of MDA-MB-231 cells, the efficacy decreased at equimolar levels from OPN (ASO-OPN-04) to BSP II (ASO-BSPII-06) and ON (ASO-ON-03). This difference could result either from differential suppression of the respective protein levels (ASO-OPN-04: 85%; ASO-BSPII-06: 75%; ASO-ON-03: 75%) or from a differential importance of the target proteins supporting colony growth. Colony formation reflects the ability of a specialized compartment of tumor cells to grow anchorage independently and to reproduce themselves in the absence of neighboring cells. Therefore, inhibition of colony formation is indicative of an inhibition of autocrine stimulation. It is noteworthy that reduced levels of all three proteins investigated were associated with inhibition of colony formation, indicating that OPN, BSPII and ON acted as direct or indirect mitogens. Since the treatment effect of the ASOs are clearly reversible, as shown by increased protein expression levels after 5 days and gain of migrating functions (own, unpublished results), the effects seen after 5-7 days (clonogenicity) and 28 days (in vivo) are related to an early inefficiency of the cells to form colonies, to migrate, or to seed into the bone compartment. The extent of response to the ASOs, which was additively increased by repeated exposure, was clearly dependent on the respective concentrations used. A mitogenic and antiapoptotic function has been described for OPN, 29, 48 reduction of such activity is consistent with reduced colony formation and hence could be useful for anticancer treatment in general. In combination with ErPC 3 , all ASOs showed additive activity, as can be derived from their combination index, respectively, that varied around 1. This is in line with the assumption that both combination partners act on different targets.
The recent description of OPN as related to tumor progression in colonic cancer 1 further supports this hypothesis. Other groups have varied the OPN expression in vivo; they described a reduced metastasis formation in the skeleton and lungs, when injecting B16 melanoma cells to OPN-deficient mice. 54 Also, when reducing OPN levels by antisense molecules, reduced tumorigenicity and clonogencity was observed in murine, ras-transformed NIH 3T3 cells and JB6 c141.5a cells, as well as in B77-Rat 1 fibroblasts. [49] [50] [51] These findings are extended by our result that exposure to an ASO directed against OPN was instrumental in inhibiting the formation of osteolytic lesions in three of four animals used, and in reducing the lesion size of the remaining rat. A similar effect in response to downmodulating BSPII-levels has not been described so far. Although slightly less active, the reduction of BSP II levels caused an effect which parallels that of reducing OPN levels.
These results suggest that reduction of OPN and BSPII levels in vivo could be instrumental for a combination treatment of cancer, specifically of osteolytic metastasis.
In conclusion, suited ASOs reduced the respective protein levels of OPN, BSPII and ON specifically. Their activities in inhibiting colony growth and formation of osteolytic bone metastasis suggest a beneficial effect in restraining the growth of metastasis in vivo, as well. Future experiments will show whether this hypothesis is justified. 
Abbreviations

